Shaily Engineering Plastics Limited (SHAILY) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Shaily Engineering Plastics is a precision plastics manufacturer whose drug-delivery devices business has become its largest segment, now supplying pen injectors into the fast-growing GLP-1 ecosystem. The Q2 FY27 print will speak to whether polymer and freight cost pass-through is on track for the guided gross-margin normalisation by Q3 FY27, and whether device volumes hold the ~9 million-per-quarter run-rate needed to exceed the 36-million FY27 pen guidance.

Shaily Engineering Plastics Limited Q2 Results Date and Time

Per the board-meeting intimation, the Board is scheduled to meet on Thursday, 29 Oct 2026 to approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30 Sep 2026. The trading window for designated persons remains closed from 01 Oct 2026 to 31 Oct 2026 under SEBI insider trading regulations.

An earnings call for Q2 & H1 FY27 (period ended 30 Sep 2026) is scheduled for Friday, 30 Oct 2026, 4:00 PM IST. Participants include Mr. Amit Sanghvi (MD) and Mr. Sanjay Shah (Chief Strategy Officer), with dial-ins available for the US, UK, Singapore and Hong Kong.

What to expect from Shaily Engineering Plastics Limited's Q2 FY27 results

The central question for Q2 FY27 is whether the May-July polymer and freight pass-through shows up in the gross-margin bridge, against input costs that stayed elevated through the quarter — domestic PVC resin moved from Rs. 78/kg in early July to Rs. 94/kg on 1 Sep 2026, and container freight held roughly 130% above pre-war levels from July through October. Management has guided gross margins to normalise by Q3 FY27, and Q2 is the first full quarter where the pass-through should be visible against a Q2 FY26 base that was the strongest of FY26 at a 31.8% EBITDA margin and 20.0% PAT margin. On volumes, Q1 delivered close to 9 million delivery devices with GLP-1 accounting for 50-60% of that volume, and management has said it is confident of exceeding the 36-million FY27 pen guidance, with the additional 25 million pen capacity expected operational by end of September 2026 to take installed capacity to ~75 million pens per annum. Healthcare became the largest segment at Rs. 142 Cr, +85% YoY and ~51% of consolidated revenue in Q1 FY27, while Consumer fell 24% YoY to Rs. 116 Cr on softer home-furnishings demand in Europe and the US — making the Consumer trajectory the swing factor for revenue against the high base. The upcoming call is also the first checkpoint on the UK subsidiary's recovery, which management attributed to a timing issue related to milestone achievement and invoice raising, with recovery expected over the next three quarters.

Key Things To Watch

Guidance tracking for Q2 FY27: Key management markers to verify on the call:

• 36 million FY27 pen volumes — Q1 delivered ~9 million devices; the remaining three quarters require an average of ~9 million devices per quarter, with management confident of exceeding the target
• Additional 25 million pen capacity — expected operational by end of September 2026, taking total installed capacity to ~75 million pens per annum
• Gross margin normalisation — guided by Q3 FY27; check whether Q2 shows pass-through recovery from the May-June/July pricing actions against the 31.8% Q2 FY26 EBITDA-margin base
• Semiconductor tray revenue — supplies to OSAT players in India to commence Q4 FY27, with ~Rs. 5 Cr capex at the existing facility
• UK subsidiary recovery — guided over the next three quarters; Q2 FY27 is the first checkpoint

Strategic initiative updates expected

• Abu Dhabi facility — AED 130-150 million (INR 300-350 crores) for ~75 million pen/auto-injectors p.a., operational by Q4 FY28; update on the 50-55% of capacity committed/indicated and ADIO financial support
• Consumer Electronics plant in Southern India — land secured, Rs. 80-100 Cr capex; 5 new components from a new customer expected in supply before end of FY27
• First pen line speed improvement of +9% achieved with a further +30% planned; second-line strategy switched to achieving 80%+ supplier efficiency before FAT and shipping

Risks to follow up

• Consumer demand trajectory in Europe/US — Q1 FY27 Consumer revenue fell 24% YoY on softer home-furnishings demand
• Ramp-up execution on a frozen FY27 order book — FY26 pen volumes of 23.3-23.5 million missed the 25-26 million guidance on capacity constraints
• Chinese GLP-1 device competition at $1.50-$1.70 pricing versus Shaily pricing above $2, and partner-specific regulatory issues in Canada and Brazil on the Rs. 423 Cr pen-injector order

Potential narrative shifts

• With Healthcare now above 50% of revenue and Consumer declining, watch whether management re-basels segment priorities or updates the FY27 priority list given on the Q4 FY26 call